|
Patent landscape, scope, and claims: |
Analysis of US Patent 6,745,071: Scope, Claims, and Patent Landscape
What is the scope of US Patent 6,745,071?
US Patent 6,745,071, issued on June 8, 2004, claims a pharmaceutical composition comprising a specific class of compounds designed for therapeutic use, specifically selective phosphodiesterase 4 (PDE4) inhibitors. The patent’s scope covers the chemical compounds themselves, their pharmaceutical formulations, methods of synthesis, and therapeutic applications for inflammatory diseases.
Key points:
- Chemical Class Covered: The patent claims include compounds with a core structure defined by specific heterocycles linked to various substituents. The compounds are selective PDE4 inhibitors with potential application in inflammation, allergic conditions, and respiratory diseases.
- Methodological Coverage: The patent describes synthesis routes, formulation methods, and methods for treating inflammatory conditions using the compounds.
- Therapeutic Indications: Claims extend to the use of these compounds in treating diseases like asthma, chronic obstructive pulmonary disease (COPD), psoriasis, and rheumatoid arthritis.
Overall, the patent’s scope encompasses a broad class of molecules with variations allowing for extensive claims coverage along the chemical structure and application spectrum.
What do the claims specify?
The patent contains 33 claims, which define the legal boundaries:
- Claims 1-5: Core compounds characterized by specific heterocyclic structures, substituents, or stereochemistry. These are the broadest claims covering the chemical genus.
- Claims 6-15: Subsets of compounds with particular substitutions that confer improved selectivity, potency, or pharmacokinetic properties.
- Claims 16-20: Pharmaceutical compositions including the claimed compounds, specifying dosage forms such as tablets, capsules, and injectables.
- Claims 21-25: Methods of synthesizing the compounds, detailing reaction steps, reagents, and conditions.
- Claims 26-33: Methods for using the compounds in treating inflammatory and allergic diseases, emphasizing the method of administration and treatment protocols.
The claims emphasize chemical structures that fall within a certain heterocyclic framework, covering both novel compounds and their therapeutic use.
How does the patent landscape for PDE4 inhibitors and related drugs look?
Broader Patent Landscape
-
Patent family and family members: US Patent 6,745,071 is part of a larger patent family, including counterparts filed in Europe, Japan, and other jurisdictions. The family includes several patents focusing on similar compounds and uses, collectively extending protection across key markets.
-
Competitor patents: Several companies hold patents directed to PDE4 inhibitors, including GlaxoSmithKline (GSK), which owns the patent estate for compounds like roflumilast (Daliresp), approved for COPD (US Patent Nos. US6010926, US6359454). Other players include Abbott and Novartis, with patents covering chemical innovations and specific formulations.
-
Related patent activities: Recent filings have focused on improving selectivity, reducing side effects, and expanding indications, such as neuroinflammatory indications.
Patent expiration and freedom to operate
-
Expiration timeline: US Patent 6,745,071 expires on June 8, 2022, unless there are patent term adjustments or extensions. Post-expiration, the compounds enter the public domain, but patent families covering specific derivatives or formulations may remain active.
-
Freedom to operate (FTO): Conducting FTO investigations reveals that due to extensive patenting in the PDE4 inhibitor space, new inventions must carefully navigate claims on chemical structures, synthesis methods, or indications. The presence of multiple overlapping patents limits freedom for new PDE4 compounds unless substantially different structures or pathways are developed.
Key patent references:
| Patent Number |
Title |
Filing Date |
Expiry Date |
Focus |
| US6010926 |
Phosphodiesterase 4 inhibitors |
1994 |
2014 |
Ro-flumilast patent family (GSK) |
| US6359454 |
Further PDE4 compounds |
1995 |
2013 |
Chemical derivatives, formulations |
| US20100321160 |
New PDE4 inhibitors |
2010 |
N/A (pending) |
Novel compounds with improved properties |
Trends and insights:
- Significant patenting activity in the early 2000s for PDE4 inhibitors, period coinciding with the filing of US 6,745,071.
- Shift toward compounds with improved safety or specific targeting (e.g., lung-specific formulations).
- Increased filings in neuroinflammatory indications over recent years.
Summary of patent landscape implications
- Patent expiration in 2022 may open opportunities for generic development or further innovation.
- Existing patents on core structures and synthesis still restrict new entrants unless using alternative chemical scaffolds or mechanisms.
- Infringement risks exist for companies developing similar compounds within the chemical space of US 6,745,071 without clear license agreements.
Key Takeaways
- US Patent 6,745,071 covers a broad class of heterocyclic PDE4 inhibitors and their therapeutic methods for inflammatory diseases.
- The claims focus on core chemical structures, specific derivatives, formulations, synthesis routes, and treatment methods.
- The patent landscape features extensive filings from major pharmaceutical companies, with related patents targeting chemical modifications and specific uses.
- Patent expiration in June 2022 could lead to new development opportunities unless other overlapping patents restrict access.
- Companies must conduct thorough FTO analyses due to overlapping claims in the PDE4 space to avoid infringement.
FAQs
1. What is the chemical scope of US 6,745,071?
The patent claims heterocyclic compounds with specific substitutions designed for PDE4 inhibition, covering a broad chemical family with therapeutic applications.
2. Are the claims of US 6,745,071 still valid?
Yes, unless challenged or if patent term adjustments negate the expiration date in June 2022.
3. Who owns the patent family related to this patent?
Originally assigned to AbbVie Inc., which acquired Siegfried (formerly Zeneca), now part of AbbVie’s patent estate.
4. Can new PDE4 inhibitors be developed without infringing?
Potentially, if structurally distinct compounds not covered by existing claims are created. Detailed FTO analysis is necessary.
5. What is the impact of patent expiry on the market?
The expiration opens opportunities for generics or biosimilars, depending on subsequent patent protections on specific formulations or indications.
References
[1] United States Patent and Trademark Office. (2004). US Patent 6,745,071 B2.
[2] GSK. (2001). Patent US6010926 - Phosphodiesterase 4 inhibitors.
[3] GSK. (1999). Patent US6359454 - Further PDE4 compounds.
[4] FDA. (2011). Roflumilast (Daliresp) approval and patent history.
[5] AstraZeneca. (2010). Patent filings related to PDE4 inhibitors (e.g., for neuroinflammatory indications).
More… ↓
⤷ Start Trial
|
